威尼托克拉克斯通过向BCL2克服了急性髓性白血病中的索拉芬尼抗性
1Department of Hematology, Nanfang Hospital, Southern Medical University, Guangzhou 510091, China.
Biology
|October 27, 2023
概括
在急性髓性白血病 (AML) 中,可利用基因特征预测索拉芬尼抗性. 将索拉芬尼与venetoclax结合使用,可以通过向AML中的JAK-STAT3/BCL2途径来克服耐药性.
科学领域:
- 血液学 血液学 血液学
- 在瘤学瘤学.
- 分子生物学分子生物学
背景情况:
- 索拉菲尼布是一种激酶抑制剂,在急性髓性白血病 (AML) 中表现出有效性,但通常会遇到临床耐药性.
- 索拉费尼布耐药性的机制和在AML中克服它的策略仍然不完全理解.
研究的目的:
- 开发一个平台,用于预测AML患者的索拉费尼布耐药性和临床结果.
- 确定有效的治疗策略,以克服AML中的sorafenib抗性.
主要方法:
- 分析索拉芬尼布耐药和对照AML患者的单细胞和批量转录数据.
- 整合索拉芬尼布耐药性基因特征,用于敏感性和结果预测.
- 使用解卷方法对scRNA-seq数据进行药物敏感性分析.
主要成果:
- 开发了一种索拉费尼布耐药性基因特征,以预测AML细胞的敏感性和患者的结果.
- 威尼托克拉克斯证明了对抗 sorafenib 耐药的 AML 细胞的有效性.
- 索拉芬尼激活了JAK-STAT3通路,对抗性AML细胞中的BCL2表达进行上调,使它们易受venetoclax.
结论:
- 成功开发了一种可预测索拉费尼布耐药性和AML临床结果的平台.
- 索拉芬尼和venetoclax的组合为AML治疗提供了一个有希望的治疗策略,特别是在抗药性病例中.
相关概念视频
Treatment Resistant Cancers
3.3K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.3K
Combination Therapies and Personalized Medicine
4.9K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.9K
Targeted Cancer Therapies
7.7K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.7K
Cancer Therapies
7.7K
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
7.7K
Adaptive Mechanisms in Cancer Cells
5.8K
Cancer cells accumulate genetic changes at an abnormally rapid rate due to the defects in the DNA repair mechanisms. From an evolutionary perspective, such genetic instability is advantageous for cancer development. Mutant cell lines accumulate a series of beneficial mutations that contribute to their progression into cancer.
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
5.8K
Renal Drug Clearance: Overview
224
Renal clearance is a crucial parameter in pharmacokinetics that quantifies the rate at which the kidneys excrete a drug. It represents a constant fraction of the central volume of distribution containing the drug that the kidney eliminates per unit of time.
Renal clearance can be calculated using different methods. One approach is to divide the urinary drug excretion rate by the plasma drug concentration. This method directly measures renal clearance, indicating the kidneys' efficiency in...
Renal clearance can be calculated using different methods. One approach is to divide the urinary drug excretion rate by the plasma drug concentration. This method directly measures renal clearance, indicating the kidneys' efficiency in...
224


